3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other solid neoplasm
2
Conditions
Breast Neoplasms
103
Carcinoma, Renal Cell
70
Neoplasm Metastasis
48
Neoplasms
37
Neuroendocrine Tumors
33
Kidney Neoplasms
27
Recurrence
19
Tuberous Sclerosis
18
Carcinoma, Non-Small-Cell Lung
17
Prostatic Neoplasms
16
Triple Negative Breast Neoplasms
15
Lymphoma
15
Lymphoma, Mantle-Cell
14
Lymphoma, Large B-Cell, Diffuse
14
Head and Neck Neoplasms
14
Glioblastoma
14
Colorectal Neoplasms
13
Carcinoma, Hepatocellular
13
Stomach Neoplasms
12
Lung Neoplasms
12
Leukemia, Lymphocytic, Chronic, B-Cell
12
Hodgkin Disease
12
Brain Neoplasms
12
Sarcoma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Pancreatic Neoplasms
11
Glioma
11
Waldenstrom Macroglobulinemia
10
Lymphoma, Follicular
10
Carcinoma, Neuroendocrine
10
Interventions
Paclitaxel
15
atezolizumab
11
Gemcitabine
11
Carboplatin
9
pembrolizumab
8
Docetaxel
8
Irinotecan
7
Bevacizumab
7
Injections
6
Cetuximab
6
Sunitinib
5
Leucovorin
5
Fluorouracil
5
Cyclophosphamide
5
Capecitabine
5
tocilizumab
4
olaparib
4
navitoclax
4
liposomal doxorubicin
4
Topotecan
4
Oxaliplatin
4
Nivolumab
4
Erlotinib Hydrochloride
4
temsirolimus
3
spartalizumab
3
pazopanib
3
lenvatinib
3
fludarabine
3
cobimetinib
3
Cisplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Solid Tumors
×
Everolimus
×
Clear all
NCT01349296
2016-05-20
BARIS
University of Cologne
Phase 1
Completed
18 enrolled
NCT00586443
2014-11-19
BEP
Duke University
Phase 1
Completed
56 enrolled